Fol News

Tutti gli approfondimenti
Tutte le notizie

HART titolo da piu 100%..o

Harvard Apparatus Regenerative TechnologyDeveloping bioengineered organs for life-threatening conditions Find GO

HomeAbout UsInvestorPress ReleasesResearch ProductsTalk to Us
Investor Resources

Email Alerts
RSS Feeds
Investor Contact
Harvard Apparatus Regenerative Technology
84 October Hill Road
Suite 11
Holliston, Massachusetts 01746
United States

Phone: (774) 233-7300
Toll Free: (855) 209-3104
Fax: (774) 233-7302
E-mail: tmcnaughton@HARTregen.com


Advanced Search

Home / Investor Relations / Press Releases / Bioengineered Organ Implant Company HART to Webcast LD Micro Presentation in Los Angeles, Tues. Dec. 1st at 2:30 pm PT
Bioengineered Organ Implant Company HART to Webcast LD Micro Presentation in Los Angeles, Tues. Dec. 1st at 2:30 pm PT
Category:
Featured
Wednesday, November 25, 2015 2:57 pm EST
Dateline:
Los Angeles, CA & Holliston, MA
EmailPDFPrintRSS
Los Angeles, CA & Holliston, MA, November 25, 2015 – Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that CEO Jim McGorry will present at the LD Micro “Main Event” investor conference on Tuesday, December 1, 2015 at 2:30 p.m. PT. The presentation will be webcast live and posted for replay (link below) for 30 days. Management will also be available at the conference for one-on-one meetings on Wednesday December 2, 2015. The conference will be held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.

Live Webcast/Replay and Presentation Slides: http://wsw.com/webcast/ldmicro9/hart

Jim McGorry will review the company’s business strategy and opportunities and comment on HART’s recent animal studies that revealed significant results from its second generation (Gen2) bioengineered implant platform for the esophagus, trachea and bronchus, as well as the company’s near-term milestones. HART has initiated confirmatory large-animal studies of its Gen2 implants in collaboration with Mayo Clinic. The study design has been completed, prerequisite tests are underway and the Company expects the animal surgeries to occur in December. HART looks to initiate human compassionate use procedures during 2016. Also, the Company plans to file an IND application with the U.S. FDA in 2016, seeking to commence clinical trials for one of HART’s three indications.

About LD Micro (LD Micro)
LD Micro is a (non-registered) investment advisor focused on finding undervalued micro-cap companies. Since 2002 the firm has published reports on select companies, and it also hosts microcap investment conferences such as the LD Micro “Main Event” each December.

About HART: (Regenerative Medicine Technology from Harvard Apparatus)
Harvard Apparatus Regenerative Technology (HART) makes bioengineered implants for life-threatening conditions. The company’s technology platform is to be used to restore function in the esophagus and the trachea and bronchus airways. HART’s first generation tracheal implant has been used successfully in five adult human implant procedures approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority. HART is completing further large-animal studies to refine its technology platform with the goal of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of the company’s three indications.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the regulatory approval of any HART products by the FDA, EMA, MHRA or otherwise, which approvals may not be obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of HART products pertaining to the airway or esophagus, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for the bioreactors, scaffolds and other devices and product candidates we pursue; the success of our clinical trials and devices; plus other factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.


Twitter: Investor Relations @HART_IR_Team
StockTwits: @HART_IR


Investor Relations:
Catalyst Global LLC
David Collins, Tanya Kamatu
212-924-9800
hart@catalyst-ir.com


Privacy PolicyLegal Notice
© 2015 Harvard Apparatus Regenerative Technology. All Rights Reserved.

Business Wire InvestorHQ℠
 
un rullo compressore me co joni:eek:
e' un titolo da +1000 non da +100:eek:
 

Allegati

  • ScreenHunter_564 Nov. 30 17.07.jpg
    ScreenHunter_564 Nov. 30 17.07.jpg
    75,1 KB · Visite: 93
Comunque per chi non fosse ancora dentro, domani c'è la LD micro, se l'authority dovesse dare il via libera per la commercializzazione a +1000 ci arriva !
 
:bow:
 

Allegati

  • ScreenHunter_566 Dec. 01 06.01.jpg
    ScreenHunter_566 Dec. 01 06.01.jpg
    85,8 KB · Visite: 47
Monday, November 30, 2015 4:35 pm EST
Dateline:
Holliston, MA
EmailPDFPrintRSS
"Maintaining our NASDAQ listing is fundamental to our corporate strategy. We are gratified by the investment community’s response to our recent progress, including the positive animal research results on HART’s second generation (Gen2) bioengineered esophageal, tracheal and bronchial implants."
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced it has received written notification from The NASDAQ Stock Market that it has regained compliance with the minimum bid price requirements. The letter noted that as a result of the closing bid price of HART’s common stock having exceeded $1.00 per share for more than ten consecutive business days, the company has regained compliance and the matter is now closed.

HART’s CEO, Jim McGorry, commented, "Maintaining our NASDAQ listing is fundamental to our corporate strategy. We are gratified by the investment community’s response to our recent progress, including the positive animal research results on HART’s second generation (Gen2) bioengineered esophageal, tracheal and bronchial implants.”

Mr. McGorry continued, “Going forward, our development plan is focused on getting our technology back into humans on a compassionate use basis and filing our first clinical trial application with the FDA during 2016. We are confident that we will meet these goals given the results of our recent studies using our Gen2 technology across all three applications, our strong scientific team and our collaborations with translational partners. We have initiated confirmatory large-animal studies of our Gen2 implants with Mayo Clinic. The study design has been completed, prerequisite tests are underway, and we expect the animal surgeries to occur in December.”

About HART (Regenerative Medicine Technology from Harvard Apparatus)
Harvard Apparatus Regenerative Technology (HART) makes bioengineered organ implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the airways (trachea and bronchus). HART is completing further large-animal studies to refine our technology platform with the goal of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates. Our first-generation trachea technology was used in five adult human trachea transplants approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority.

Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the development expectations and regulatory approval of any HART products by the FDA, EMA, MHRA or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of HART products, including those pertaining to the airway or esophagus, which such success may not be achieved or obtained on a timely basis or at all . These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for the our implant products, bioreactors, scaffolds and other devices and product candidates we pursue; plus other factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Investor and Media Contact:
David Collins, Tanya Kamatu
Catalyst Global
212 924 9800
hart@catalyst-ir.com
 
Non lo guarda più nessuno questo titolo?
A gennaio dovrebbero comunicare i risultati dgli ultimi test, é pronta per fare un altro +100
 
Ops.. Ho provocato qualcuno ? Ha appena fatto un + 10 - 5 ..
 
Oggi ha chiuso con un +12 news in arrivo?
 
Della mia lunga watch list questa è l'unica che ha chiuso verde oggi.
Lunedí fa i fuochi d'artificio.
 
Io ho inserito il tp valido fino a venerdí prossimo a 4€
 
Devi accedere o registrarti per poter rispondere.
Indietro